Pronunciation:
ran-i-bi-zoo-mab
Trade Name(s)
Ther. Class.
ocular agents
Pharm. Class.
monoclonal antibodies
Binds to vascular endothelial growth factor A (VEGF-A) receptor sites, preventing the binding of endogenous VEGF-A, resulting in decreased endothelial proliferation, vascular leakage and new vessel formation.
Therapeutic Effect(s):
Decreased progression of visual loss.
Absorption: Intravitreal injection results in complete local bioavailability. Very low serum levels are achieved.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 9 days (intravitreal).
TIME/ACTION PROFILE
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
intravitreal | unknown | after injection | 1 mo |
Contraindicated in:
Use Cautiously in:
EENT: conjunctival hemorrhage, eye pain, ↑ intraocular pressure, intraocular inflammation, vitreal floaters, endophthalmitis, retinal detachment
CV: MI, STROKE
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
↑ risk of serious intraocular inflammation with verteporfin.
Macular Degeneration
Intravitreal (Adults): 0.5 mg once monthly; after 4 mo, injections may be given every 1–3 mo.
Macular Edema Following Retinal Vein Occlusion
Intravitreal (Adults): 0.5 mg once monthly.
Diabetic Macular Edema and Diabetic Retinopathy
Intravitreal (Adults): 0.3 mg once monthly.
Myopic Choroidal Neovascularization
Intravitreal (Adults): 0.5 mg once monthly for up to 3 mo. May be retreated if needed.
Solution for intravitreal injection: 0.3 mg/0.05 mL (vial or prefilled syringe), 0.5 mg/0.05 mL (vial or prefilled syringe)
Do not administer solutions that are discolored or contain particulate matter. Attach threaded plastic threader rod to the rubber stopper inside barrel of syringe. Do not pull back on plunger.
Advise patient to notify ophthalmologist immediately if eye becomes red, sensitive to light, painful, or develops a change in vision.
Slowing of vision loss.
ranibizumabis the Anesthesia Central Word of the day!